Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Tomomi Kokubo
Poor Outcome With Anti-Programmed Death-Ligand 1 (PD-L1) Antibody Due to Poor Pharmacokinetic Properties in PD-1/PD-L1 Blockade-Sensitive Mouse Models
Journal for ImmunoTherapy of Cancer
Oncology
Molecular Medicine
Pharmacology
Cancer Research
Allergy
Immunology
Related publications
Programmed Death Ligand 1 (PD-L1) Expression in Primary Angiosarcoma
Journal of Cancer
Oncology
PD-1 Receptor (PDCD1; PD-1; CD279); Programmed Cell Death 1 Ligand 1 (CD274 Molecule; PD-L1; B7-H1)
Science-Business eXchange
Comprehensive Immunohistochemical Study of Programmed Cell Death Ligand 1 (PD-L1)
American Journal of Surgical Pathology
Anatomy
Forensic Medicine
Pathology
Surgery
Clinicopathologic Significance and Immunogenomic Analysis of Programmed Death-Ligand 1 (PD-L1) and Programmed Death 1 (PD-1) Expression in Thymic Epithelial Tumors
Frontiers in Oncology
Cancer Research
Oncology
Diverse Cutaneous Adverse Eruptions Caused by Anti-Programmed Cell Death-1 (PD-1) and Anti-Programmed Cell Death Ligand-1 (PD-L1) Immunotherapies: Clinical Features and Management
Therapeutic Advances in Medical Oncology
Oncology
Sarcomatoid Lung Carcinomas Show High Levels of Programmed Death Ligand-1 (PD-L1)
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
Oncolytic Virus and PD-1/PD-L1 Blockade Combination Therapy
Oncolytic Virotherapy
Programmed Cell Death Ligand 1 (PD-L1) Signaling Regulates Macrophage Proliferation and Activation
Cancer immunology research
Cancer Research
Immunology
2241. Outcomes of Program Cell Death Protein 1 (PD-1) and Programmed Death-Ligand 1(pd-L1) Inhibitor Therapy in HIV Patients With Advanced Cancer
Open Forum Infectious Diseases
Oncology
Neurology
